Skip to main content
S

SCL Science Inc. — Investor Relations & Filings

Ticker · 246960 ISIN · KR7246960009 KO Professional, scientific and technical activities
Open in API
Filings indexed 309 across all filing types
Latest filing 2026-03-31 Declaration of Voting R…
Country KR South Korea
Listing KO 246960

About SCL Science Inc.

https://sclscience.com/en

SCL Science Inc., formerly InnoTherapy Inc., is a healthcare company focused on digital innovation and advanced medical technologies. The company develops and commercializes medical hemostatic agents based on its proprietary biomimetic technology, including the Bio-inspired Medical Materials (BiMM) product line. Leveraging 40 years of expertise in medical science, SCL Science is also dedicated to building a digital healthcare ecosystem using artificial intelligence and high-quality medical data. Its services extend to clinical trial analysis, bio-logistics, and an expanding drug discovery platform focused on AI-driven cancer vaccine development. The company serves hospitals, research laboratories, and other medical institutions.

Recent filings

Filing Released Lang Actions
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is titled “정기주주총회결과” (Annual General Meeting Results) and details the resolutions voted on at the AGM, including financial statement approvals, director and auditor appointments, vote counts, and percentages. It reports the official voting results for each agenda item. This matches the definition of a Declaration of Voting Results & Voting Rights Announcement. It is not a full annual report, proxy solicitation, or management presentation but specifically a vote-results announcement for the AGM.
2026-03-31 Korean
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Board/Management Information Classification · 1% confidence The document is a regulatory disclosure titled “사외이사의 선임·해임 또는 중도퇴임에 관한 신고,” detailing the appointment and dismissal of outside directors at the company, filed with the Financial Services Commission/Korea Exchange. This is clearly an announcement of changes in the company’s board of directors, matching the Board/Management Information category.
2026-03-31 Korean
소송등의제기ㆍ신청(경영권분쟁소송) (의안상정가처분)
Legal Proceedings Report Classification · 1% confidence The document is a corporate announcement in Korean detailing the initiation and withdrawal of a lawsuit (management dispute litigation), including case title, plaintiffs, petition details, court jurisdiction, and related dates. This clearly constitutes an update on significant legal proceedings involving the company, fitting the "Legal Proceedings Report" category.
2026-03-30 Korean
사업보고서 (2025.12)
Audit Report / Information Classification · 1% confidence The document is the independent auditor’s report (“감사보고서”) for the fiscal year ending December 31, 2025, prepared by an external audit firm. It contains the auditor’s opinion, key audit matters, management and auditor responsibilities, and the full set of audited financial statements with notes. It is not an earnings release, annual management discussion, or presentation, but a standalone audit report. Therefore, it fits the definition of Audit Report / Information (Code: AR). FY 2025
2026-03-23 Korean
감사보고서제출
Audit Report / Information Classification · 1% confidence The document is titled “감사보고서 제출” and contains detailed audit opinions on consolidated and separate financial statements (audit opinions, financial data, audit firm name, audit report date). It is a standalone audit report submission, not an annual report or earnings release. Therefore, it fits the Audit Report / Information category. FY 2025
2026-03-23 Korean
[기재정정]의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 1% confidence The document is titled '의결권대리행사권유참고서류' (Reference Document for Solicitation of Proxy) and is a regulatory filing submitted by SCL Science to the Financial Supervisory Service (FSS) in South Korea. It contains information regarding the solicitation of proxies for the upcoming Annual General Meeting (AGM), including the purpose of the solicitation, details of the proxy solicitor, and the agenda items (such as the approval of financial statements and appointment of auditors). While it contains financial statements, these are provided as supporting information for the proxy solicitation process rather than as a standalone Annual Report (10-K) or Interim Report (IR). Therefore, it is classified as a Proxy Solicitation & Information Statement.
2026-03-18 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.